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The field of genomics has expanded into subspecialties such as metagenomics over the
course of the last decade and a half. The development of massively parallel sequencing
capabilities has allowed for increasingly detailed study of the genome of the human micro-
biome, the microbial super organ that resides symbiotically within the mucosal tissues
and integumentary system of the human host. The gut microbiome, and particularly the
study of its origins in neonates, has become subtopics of great interest within the field of
genomics.This brief review seeks to summarize recent literature regarding the origins and
establishment of the neonatal gut microbiome, beginning in utero, and how it is affected by
neonatal nutritional status (breastfed versus formula fed) and gestational age (term versus
preterm). We also explore the role of dysbiosis, a perturbation within the fragile ecosys-
tem of the microbiome, and its role in the origin of select pathologic states, specifically,
obesity and necrotizing enterocolitis (NEC) in preterm infants. We discuss the evidence
supporting enteral pre- and pro-biotic supplementation of commensal organisms such as
Bifidobacterium and Lactobacillus in the neonatal period, and their role in the prevention
and amelioration of NEC in premature infants. Finally, we review directions to consider for
further research to promote human health within this field.
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INTRODUCTION
The evolution of the field of genomics, spurred largely by the
Human Genome Project, has given rise to metagenomics, or
“the application of modern genomics techniques to the study
of communities of microbial organisms directly in their natural
environments” (1). This burgeoning area of study has resulted
in significant advances in whole-genome analysis techniques that
have greatly facilitated the study of the human microbiome.
The human microbiome is a microbial community best
described as“the sum of all microbial life living in or on the human
body” (2). It is an entity that has wide-reaching metabolic, nutri-
tional, and immunological effects on the host, and as such has
generated a great deal of interest within the biomedical research
community. The microbiome evolves within a healthy host from
birth to death, constantly fine-tuning it to maintain a homeostatic
balance with the host’s immune system. Continued evolution of
the human microbiome after birth is governed by host factors such
as both the adaptive and innate immune system, as well as external
factors such as diet, medication and toxin exposure, and illness (3,
4). Of particular interest is the study of the gut microbiome, its
evolution beginning in utero and across the lifespan, its effect on
promotion of health, and its role in the development of disease.
The purpose of this brief review is to introduce the reader to the
concept of the human microbiome and to summarize recent liter-
ature specifically regarding the neonatal gut microbiome, from its
establishment at birth through its evolution during early infancy.
We review differences in microbial colonization and immune func-
tion of the intestinal tract in healthy full-term newborns compared
with their preterm very low birth weight (VLBW) (birth weight
<1500 g) counterparts and the implications for development of
disease when the microbiome is disrupted (dysbiosis). Finally, we
describe the role of probiotic use as a potential factor involved in
governing development of a “healthy” gut microbiota and discuss
areas of further research warranted to deepen our understand-
ing of this complex ecosystem and its role in human health and
disease.
ESTABLISHMENT AND EVOLUTION OF THE NEONATAL GUT
MICROBIOME
The first, and most important, contribution to the genesis of the
microbiome is vertical transmission of maternal microbiota. Col-
onization of mucosa in the digestive, respiratory, urogenital tracts,
as well as the skin begins at, or perhaps even before, the time of
birth when a newborn is exposed to a mother’s microbiota. It was
previously thought that the in utero environment was largely ster-
ile and that a fetus was not colonized with bacteria until the time of
birth. Recent studies suggest the presence of a microbiome within
the placenta as well as fetal meconium, suggesting that the colo-
nization process begins well before delivery. Aagaard et al. have
recently characterized a placental microbiome profile, composed
of non-pathogenic commensal microbiota from the Firmicutes,
Tenericutes, Proteobacteria, Bacteroidetes, and Fusobacteria phyla
which, interestingly, shares some similarities with the human oral
microbiome (5). They observed that in the first week of life the full-
term neonatal gut microbiome is largely colonized by members of
the Actinobacteria, Proteobacteria, Bacteroidetes, and, much less,
Firmicutes phyla (Figure 1) (5, 6). This is contrasted with the pre-
viously described finding that neonates weighing <1200 g have a
gut microbiome dominated by members of both Firmicutes and
Tenericutes phyla (5, 7, 8). This evidence of early colonization
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FIGURE 1 | Classification of common bacteria found in neonatal intestinal microbiome.
of the neonatal gut microbiome so close to the time of birth
suggests that there may be exposure to an antenatal source of
commensal bacteria, such as the placenta, and this seeding may
vary by length of gestation (5). It is well known that as fetuses
become more neurologically mature, they begin to swallow large
amounts of amniotic fluid, particularly during the third trimester
of pregnancy. If the uterine environment is colonized with its own
microbiota, as is suggested in recent studies, then the fetal gut
may in turn become colonized by these organisms. Recent stud-
ies suggesting that meconium is not sterile support this theory
(9). Ardisonne et al. evaluated meconium samples from neonates
and found that bacterial species in meconium were shared with
organisms found in the amniotic fluid (10).
As such, the gastrointestinal (GI) tract has the greatest diver-
sity and abundance of microbes and evidence is mounting that it
becomes colonized antenatally. Approximately 100 trillion organ-
isms – which is 10 times the total number of cells in the human
body – typically comprise the gut microbiota and the majority of
these populate the distal ileum and colon. More than 99% of the
gut microbiota is anaerobes (6, 11). Interestingly, each individual’s
microbiome is populated by only 15% of the 1000 plus species of
intestinal bacteria already described, leading to significant inter-
individual variability of the microbiome (4, 12). Eckburg et al.
examined 13,355 prokaryotic ribosomal RNA gene sequences from
intestinal mucosal tissue samples and fecal samples of healthy adult
subjects and observed that of 395 bacterial phylotypes identified,
244 were novel, and 80% represented sequences from species that
have not been cultivated (13).
It is easy to conceptualize then that the collective genome of
the intestinal microbiota is >100 times the number of genes in the
human genome; as such, there are a significant potential number of
commensal antigens for the host immune system to encounter and
to respond. This exceeds the number of self and pathogen-based
antigens a human will encounter in their lifetime (12).
Infants born via vaginal delivery have intestinal colonization
reflective of maternal vaginal flora such as Lactobacillus and Pre-
votella species. Infants born via Cesarean delivery are colonized by
epidermal rather than vaginal species, such as Clostridium, Staphy-
lococcus, Propionobacterium, and Corynebacterium and they have
a deficiency of anaerobes with lower numbers of Bacteroides and
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Bifidobacterium when compared to vaginally born infants (14–
18). Thus, the mode of delivery appears to have an influence on
the diversity and function of an infant’s microbiota, which can per-
sists for months and, perhaps longer, after birth. Jakobsson et al.
demonstrated that full-term infants delivered via Cesarean section
lacked or displayed delayed gut colonization by members of the
Bacteroidetes phylum by up to 1 year, with an overall lower total
microbial diversity (19). Other studies have also shown persistent
differences in intestinal microbial colonization between Cesarean-
delivered and vaginally delivered children as far as 7 years of
age (20).
Further development of the neonatal gut microbiome after
birth, regardless of mode of delivery is governed by interaction
between the microbiota and the host’s immune system. The pro-
gression of how this evolves remains incompletely characterized
and many questions remain surrounding the true origins of the
microbes that colonize the neonatal gut and what factors underlie
inter-infant differences in gut microbiota, Palmer et al. evaluated
stool samples of 14 healthy full-term infants using rDNA microar-
ray technology to define their gut microbial profiles over the course
of their first year of life and found that while at a phylum level
diversity of the analyzed samples was mostly limited to Flexibac-
ter–Cytophaga–Bacteroides, Proteobacteria, and Firmicutes and
Actinobacteria; there was a remarkable level of inter-individual
variation from baby to baby over the course of the study (21). They
noted an overall earlier appearance of aerobes such as Staphy-
lococcus, Streptococcus, and Enterobacteria; a later appearance of
anaerobes such as Eubacteria and Clostridium, and variable tim-
ing of the emergence of Bacteroides, which ultimately established
a presence in all babies by age 1 year. Transient colonization was
noted at varying time points by other organisms including Pre-
votella, Acinetobacter, Desulfovibrio, Veillonella, and Clostridium
perfringens (21). In contrast, a 2012 study by Turroni et al. demon-
strated Bifidobacteria species as a predominant component of the
term infant gut microbiota, challenging the notion that the infant
gut contains low numbers of Bifidobacterium (22). The differ-
ences seen between these studies highlights the need for cautious
further investigation to best characterize the infant gut micro-
biome. Nevertheless, gut colonization patterns established within
the first week of life are thought to have effects on the compo-
sition of the individual’s future gut microbiota via a variety of
factors (17, 19, 23, 24). The term infant’s gut microbiome under-
goes rapid maturation over the first year of age and is securely
established in an adult form by 3 years of age. An individual’s
ultimate adult gut microbiome profile is likely governed by an
elucidated interplay between initial colonizing microbiota, genes,
normal gut development, diet, and environment (14, 21, 25, 26).
Once established, the intestinal microbiome engages in a sym-
biotic relationship with its host. The neonatal immune system
will rapidly mature secondary to influence of microbiota, diet,
exposure to new microbes, xenobiotics, and other environmen-
tal exposures (12). The organisms that comprise the microbiota
benefit from the warm, nutrient-rich environment afforded by the
gut. This allows for optimum growth within a stable ecosystem.
The human, in turn, benefits from activities of the microbiota that
primarily allow for an increased digestive capacity and an abil-
ity to harvest nutrients from food. Weaning from breast milk or
formula and introducing solid foods causes a shift in composi-
tion of the neonatal gut microbiome and leads to increased counts
of Bacteroides, Clostridium, and anaerobic species of Streptococcus
but decreased numbers of Bifidobacterium. This shift in bacterial
makeup leads to expression of bacterial genes that are involved
both in degradation of xenobiotic compounds, vitamin biosyn-
thesis, and production of other metabolites such as butyrate and
acetate (21, 25, 27, 28). In addition to these pro-nutrient effects,
the intestinal microbiome can limit nutrient resources available
to pathogens, specifically by out-competing them for metabolic
resources and for physical space (12, 27). Gut microbiota also
aid in development of barrier function, integrity, and systemic
immune function. This includes formation of a tolerant state
between gut organisms and the immune system and is thought
to affect tight junction structure and function (3, 29). Generation
of pro-inflammatory or anti-inflammatory responses as a result
of exposure to bacteria include activation or deactivation of toll
like receptors, T-lymphocyte activation, and triggering secretion
of pro- and anti-inflammatory interleukins and cytokines, as well
as activation of B-cells within the mesenteric lymph node system
(3, 25) – the scope of which is beyond this present review. Overall,
these arms of the innate and adaptive immune system interact with
the microbiota to establish normal digestive capabilities, gut motil-
ity, immune tolerance to foods and certain microbial antigens, and
protection against pathogens (25). The exact role of the neonatal
gut microbiome in the development and maturation of the infant
immune system, as well as the influence of the neonatal immune
system on governance of the fledgling gut microbiome is still
poorly understood from a mechanistic standpoint and continues
to be a growing area for further research (27).
THE ROLE OF NUTRITION IN DEVELOPMENT OF THE
FULL-TERM NEONATAL GUT MICROBIOME
Nutrition, be it breast milk or formula, has been demonstrated
to play a major role in early colonization patterns of the neona-
tal gut microbiota. Healthy, full-term breastfed infants receive a
mix of nutrients, bacteria, and antimicrobial proteins, such as
carbohydrates, fatty acids, and lactoferrin along with secretory
IgA (sIgA) from their mother’s milk that will affect the milieu
within which their own microbiota will develop (27). Oligosac-
charides, glycoconjugates, and natural components of human milk
are also thought to prevent the attack of enteropathogens and
stimulate growth of Bifidobacterium (4, 30, 31). These human
milk oligosaccharides are known to directly interact with the sur-
face of pathogenic bacteria, and various oligosaccharides in milk
are believed to inhibit the binding of pathogens and toxins to
host cell receptors (32). Other constituents of human milk, such
as interleukin-10, epidermal growth factor, transforming growth
factor-β1, and erythropoietin, can represent important mediators
in the inflammatory response against bacterial pathogens within
the gut (4).
Live bacteria are also found in human milk, including Staphy-
lococcus, Streptococcus, Bifidobacterium, and Lactobacillus (33).
Several associated factors influence the dynamic composition of
the breast milk microbiota, including maternal health and mode
of delivery (34). At least some of the bacteria present in the
maternal gut is thought to reach the mammary gland through
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an endogenous route, the so-called enteromammary pathway and
likely contributes to the bacterial composition of breast milk (17).
The composition of breast milk bacteria becomes increasingly
less diverse, beginning with typical skin- and enteric-type organ-
isms in colostrum to less diverse flora with greater infant oral
and skin microbiota as lactation progresses (35). Non-digestible
carbohydrates found in breast milk ferment in the colon and pro-
mote further growth of probiotic Bifidobacterium and Bacteroides
species (27). Interestingly, it has also been noted that during lacta-
tion, the cells of the maternal intestinal lymphoid tissue travel via
the lymphatic and vascular circulations to the breast, facilitating
the transfer of maternal intestinal and mammary skin microbiota
to the breast-fed newborn (4, 36).
Formula-fed infants are exposed to a different array of carbo-
hydrates, bacteria, and nutrients, which leads to different coloniza-
tion patterns and immunomodulatory effects on their developing
gut microbiota. In contrast to human milk oligosaccharides as
mentioned earlier in this section, oligosaccharides currently added
to infant formula are structurally different from those naturally
found in human milk and, therefore, are unlikely to mimic some
of the structure-specific effects on the gut that are seen in breast-
fed neonates (32). It has been demonstrated that term breastfed
infants have a gut microbiota dominated by species of Bifidobac-
terium but decreased Enterobacteria. Formula-fed counterparts,
regardless of milk-based or soy-based formula composition, have a
gut microbiota comprising a more diverse array of bacteria includ-
ing Escherichia coli,Clostridium difficile,Bacteroides,Prevotella, and
Lactobacillus (14–16, 27, 37–40) (Table 1). Interestingly, even rela-
tively small amounts of formula supplementation of breast-fed
infants will result in shifts from a breast-fed to a formula-fed
pattern (41, 42). A 2011 study by Hascoet et al. demonstrated, how-
ever, that infants, who received a formula low in phosphate and
protein, comprise mainly whey protein in an attempt to provide a
composition closer to human milk, developed a stool microbiota
profile similar in Bifidobacteria composition to that for breast-fed
infants (43). This suggests that even in infants not receiving exclu-
sive breast milk, a breast-fed gut microbiota could be achieved, in
part at least, by supplementing with a type of formula having a
composition similar to breast milk.
In breast-fed infants, transmission of sIgA from the mother is
reflective of her own microbiota and confers a protective effect
Table 1 | Major differences in neonatal gut colonization by type of
feeding.
Breast fed Formula fed
Bifidobacteriaa Bifidobacteria species
Enterobacteria species Escherichia coli
Clostridium difficile
Bacteroides species
Prevotella species
Lactobacillus species
aBreast-fed infants have more colonization with Bifidobacteria species than their
formula-fed counterparts.
against pathogens that could lead to dysbiosis, the disruption of
a healthy, functional infant microbiome. sIgA is also thought to
shield the neonatal immune system from its own microbiota while
host defenses are maturing. The purported mechanisms for this
are binding of microbial antigens by sIgA and activation of the
host’s innate immune system in a more “tolerogenic” mode upon
antigen exposure. This promotes formation of regulatory immune
networks that further govern development and function of the gut
microbiome (12).
This difference in colonization and transmission of immune-
modulating factors between breast and formula-fed infants may
have far reaching effects over the course of a human’s life as it
may impact disease risk. The gut microbiota’s metabolic activity,
specifically its ability to extract nutrients from food consumed by
its host, may have a variable effect, depending on species diver-
sity and composition, on an infant’s ability to store and utilize
energy efficiently (14). An increasingly investigated avenue is the
relationship between alterations in the gut microbiome and its
possible involvement in the development of disease later in life. A
prime example of this is the obesity epidemic, which may begin
as early as the perinatal period. While this epidemic is thought to
be primarily due to excessive consumption of carbohydrates and
fats coupled with decreased physical activity, childhood obesity
has been, “in part, attributed to the fetus exposure to unfavorable
conditions (e.g., nutritional and hormonal dysfunctions) in the
uterine life, which can then exert a strong impact on the subse-
quent development, structure, and function of the child organism”
(4, 44). This phenomenon, which can extend to perinatal and post-
natal age, is known as disease programing during the development
phase (4, 45).
As previously noted, the gut microbiota serves a critical meta-
bolic function for its host. In particular, it enables digestion
of otherwise indigestible carbohydrates and triggers activation
of lipoprotein lipase. This leads to glucose absorption and stor-
age of fatty acids and thus to excessive weight gain. Increased
numbers of Firmicutes and decreased Bacteroidetes in the gut
microbiota have also been shown in experimental animal models
to predispose toward excess energy storage and obesity (46, 47).
Production of metabolites such as short chain fatty acids such as
butyrate and acetate by early commensal gut microbiota may play
a role in epigenetic alteration of gut epithelium and immune func-
tion that predispose to diseases like obesity (25, 48). Kalliomaki
et al. demonstrated increased Bifidobacterium in fecal samples dur-
ing the first year of life in children who remained normal weight at
7 years of age when compared to children who became overweight
(46). Luoto et al. later reinforced this finding by demonstrating in
a 2011 longitudinal study of 30 obese children that obese subjects
had lower levels of Bifidobacterium as infants when compared to
normal weight counterparts (49). VLBW infants are paradoxically
at increased risk for development of obesity later in life possi-
bly due to metabolic programing that predisposes toward energy
storage even when nutrients are not in short supply. An alternative
hypothesis, which could explain this predisposition toward obesity
in this population centers around altered nutrient processing and
utilization and immune regulation, has a function of altered gut
microbiota (25). To date, little research has been done to evaluate
the effect of composition of the neonatal gut microbiota, term or
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preterm, its relationship to early nutritional status, and its effect
on later development of obesity and other pro-inflammatory dis-
ease states. Given obesity’s long-reaching effects across the lifespan,
seeking to further understand its origins and metabolic underpin-
nings, perhaps beginning as early as the neonatal period, remains
an important focus of continued investigation.
THE PRETERM GUT MICROBIOME
Preterm infants, particularly VLBW infants, are at a disadvantage
when it comes to development of a healthy microbiome. Factors
contributing to this are not limited to their gut immaturity, and
also include preterm rupture of membranes, maternal infection,
increased incidence of Cesarean delivery, perinatal and postnatal
broad-spectrum antibiotic exposure as well as exposure to other
gut-modifying medications such as H2 blockers, altered gut motil-
ity, periods of fasting, intensive care infection control standards
and selection for resistant microbes, and decreased exposure to
human milk (17, 25, 29, 50). Given these factors, it seems likely,
and has indeed been shown to be true that a preterm infant’s
gut microbiota has reduced microbial diversity coupled with an
increase in colonization with pathogenic organisms (17, 51). Addi-
tionally, the preterm gut microbiome is less stable compared to
that of term counterparts and is also thought to be delayed in
transition to an adult colonization pattern (3, 14, 25, 29). Arbo-
leya et al. demonstrated this by comparing full-term breastfed
vaginally delivered infants with preterm infants with regard to
differences in representation of 18 microbial groups within gut
flora. They demonstrated that when compared with full-term
infants, preterm infants showed increased populations of faculta-
tive anaerobes such as Enterococcus, Enterobacter, and Lactobacillus,
increased numbers of Staphylococcus, and decreased numbers of
anaerobes like Bifidobacterium, Bacteroides, and Atopobium (3, 29,
52). A 2007 study by Butel et al. found that healthy full-term
breastfed infants are colonized by Bifidobacterium by day 7 of
life, whereas preterm infants are not. Interestingly, they also sug-
gest that there may be gestational age thresholds for colonization
with certain microbes – 33 weeks appears to be the milestone for
appearance of Bifidobacterium species, the organism most com-
monly implicated in development and maintenance of a healthy
gut microbiome (53). Very recently, LaRosa et al. used 16s rRNA
gene pyrosequencing to show a reproducible longitudinal succes-
sion of bacterial classes from Bacilli to Gammaproteobacteria to
Clostridia in 58 VLBW infants born at 23–33 weeks gestational
age in a single neonatal intensive care unit (NICU). They found
that this evolution was marked by periods of “abrupt population
changes” that ultimately achieve a common endpoint wherein by
33–36 weeks postconceptional age, study infants consistently had
gut microbiota predominantly colonized by anaerobes, particu-
larly Clostridia, which approached levels of older individuals. Of
note, mode of delivery, antibiotic exposure, mode of feeding, and
age of infants at time of sampling only affected the rate of pro-
gression toward an anaerobic-dominated microbiota in the study
infants, and not the sequence to achieve it (54). A 2013 study of
longitudinal development of the preterm gut microbiome in twins
also demonstrates that they share similar gut microbiome devel-
opment even within the complex, multiexposure environment of
a NICU suggesting that in preterm infants, development of the
gut microbiome may also be influenced by genetics (51). While
the evolution of the term infant gut microbiome has been some-
what characterized, to date, there are still few prospective studies
of the evolution of the preterm, VLBW gut microbiome to assess
if there is a characteristic patterned succession and time course
of microbial colonization for this group from birth through early
childhood.
In addition to altered microbial diversity as described above,
premature infants are both qualitatively and quantitatively
immunodeficient, owing to their underdeveloped immune sys-
tems. They have suboptimal gut epithelial cell barrier function
at baseline, predisposing them to invasion by pathogens that in
turn can trigger exaggerated inflammatory responses by their still-
developing immune system that may lead to disease processes
such as necrotizing enterocolitis (NEC) (16, 55). This immune
dysfunction, coupled with low diversity of gut microbiota and pos-
sibly an overall predominance of pathogenic bacteria within the
preterm intestinal microbiome has been noted in at-risk preterm
neonates with life threatening Enterobacter and coagulase nega-
tive Staphylococcus sepsis, and is a prime example of dysbiosis
(14, 56, 57).
DYSBIOSIS
Even after the microbiome is well established in healthy infants,
dysbiosis, or shifts in microbial composition or diversity, can occur
in the setting of dietary changes, antibiotic exposure, or infection.
Dysbiotic conditions can favor invasion and growth of patho-
genic species and can disrupt the finely tuned regulatory circuits
of the immune system that maintain a system of pro- and anti-
inflammatory checks and balances. The neonatal microbiome, in
healthy full-term infants and especially in preterm infants given
its dynamic nature, is fragile and impressionable. As such, the
microbiome is extremely susceptible to external influences that
can dramatically affect the short- and long-term health of the
host. The development of NEC in the preterm population is a
multifactorial, devastating, and as yet poorly understood disease
process. A link between NEC and a microbial etiology has been
recognized for decades and has been corroborated by outbreaks in
NICUs, the presence of pneumatosis intestinalis as a likely byprod-
uct of bacterial fermentation, and the often concomitant presence
of bacteremia (58). As such, NEC is increasingly thought to be,
at least in part, related to a perturbation of intestinal immune
homeostasis, and a generalized disturbance of normal coloniza-
tion patterns within the developing gut, rather than growth of a
single pathogen (59, 60). The advent of a variety of techniques
for metagenomic analysis of the developing human gut micro-
biome has given way to studies investigating whether there is
a signature microbial pattern that predisposes to or heralds the
onset of NEC. As summarized by Berrington et al., recent analyses
of microbiomic data from preterm infants with NEC show great
variability in proposed dysbiotic growth patterns (3). Some stud-
ies implicate increased Proteobacteria and decreased Firmicutes in
the development of NEC (61), while others note more than one
pattern of dysbiosis within a given neonatal cohort. Morrow et al.
noted both Firmicute dominant and Proteobacteria dominant pat-
terns within their cohort of preterm infants, the former being
associated with earlier presentation of NEC, the latter with later
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presentation (62). Alternatively, other groups have found no dif-
ferences in microbiota between NEC-affected patients and healthy
controls (63).
THE ROLE OF PRE- AND PRO-BIOTICS IN DEVELOPMENT OF
THE NEONATAL GUT MICROBIOME
Given the relative instability and impressionability of the devel-
oping gut microbiome in early life, coupled with its purported
disease prediction, detection, and treatment benefits, it seems log-
ical to explore avenues within which evolution and maintenance
of a healthy gut milieu can be promoted. One such intervention
that has gained overwhelming popularity over the last two decades,
but that remains a controversial topic, is the use of pre- and pro-
biotics. Given that an infant’s health and well-being are tightly
linked to the development of the intestine and its digestive and
immune capacities, it would seem logical that manipulation of the
microbiota with the use of pre- and/or pro-biotic nutritional sup-
plementation at an early stage could have a high and long-lasting
impact (11).
Prebiotics are “non-digestible food ingredients that selectively
stimulate the growth or activity of anaerobic/microaerophilic flora
(Bifidobacterium/Lactobacillus) in the colon of mammals” (55).
Some studies also suggest that in addition to promoting growth
of commensal organisms like Bifidobacterium and Lactobacillus,
prebiotics may also improve intestinal motility and gastric emp-
tying (64–66). These sugars are present in several food sources,
including breast milk and commercially available infant formulas.
Lactoferrin is a natural component of human milk with antimi-
crobial, immunostimulatory, and immunomodulatory properties
and has been shown to promote a gut environment in neonates
that predisposes toward colonization with favorable bacterial such
as Bifidobacterium and Lactobacillus species (67). Mastromarino
et al. recently demonstrated that early high levels of fecal lactofer-
rin in neonates may contribute to the immunologic maturation
and overall health of the newborn by promoting colonization
with Bifidobacterium and Lactobacillus species, particularly in
preterm infants (67). Inulin, lactulose, and short chain fructo-
oligosaccharides (FOS) and galacto-oligosaccharides (GOS) are
several other well-studied prebiotics in humans, but their use,
efficacy, and safety in the neonatal population, particularly the
preterm neonatal population, is not well studied (55).
Probiotics are live microorganisms that when administered in
adequate amounts, ideally confer a health benefit on the host – as
defined by the World Health Organization (WHO). Probiotic sup-
plementation in the preterm neonatal population is purported to
promote acquisition of normal commensal gut flora in these com-
promised hosts and to confer a protective effect against dysbiotic
conditions such as NEC.
Several recent clinical trials and meta-analyses on this subject
suggest that probiotic administration for NEC prevention is over-
all thought to be safe and effective (68). It is important to note,
however, that the significant degree of heterogeneity among stud-
ies included in these meta-analyses renders conclusions about the
safety and efficacy of probiotics in the vulnerable preterm pop-
ulation up for debate (55, 69). To date, virtually all trials use
combinations of different probiotics. Common probiotic prepara-
tions given to neonates include Lactobacillus and Bifidobacterium.
Probiotic preparations that recently have been studied in the
neonatal population are summarized in Table 2. Of note, of the
12 trials described in the table, 4 of them cite no difference in
NEC prevention between treatment and placebo groups. Further
examination of Table 2 highlights a notable degree of study to
study variability in terms of inclusion criteria, type, and dose of
probiotic administered. In addition, in one study, a fungal species
(Saccharomyces) is used as a probiotic. This diversity in design and
execution of clinical studies of probiotics in neonates is also evi-
dent in the recent meta-analyses by Deshpande et al., and Wang
et al., a systematic review by Mihatsch et al. and a 2014 Cochrane
review (69–72). These factors may, in part, underlie the variability
of outcomes related to NEC prevention. Janvier et al. has com-
mented that across recent trials “subgroup analyses demonstrate
little difference in the effects of probiotics between those con-
taining lactobacilli, those containing just Bifidobacteria, and those
containing a mixture, although there are trends suggesting that a
mixture of different organisms may be more effective than a single
species,” but this continues to require further study (73, 74).
Another important consideration in evaluating whether or not
the use of probiotics in this population is warranted is the effec-
tive dose and duration of treatment. In order to produce health
effects, probiotic organisms need to be able to survive within the
GI tract and persist at high levels within the intestine (86), but the
minimum effective dose at which this can be achieved remains to
be determined. Historically, the ability to reliably determine what
organisms colonize the intestinal tract has been limited by use
of plate culture methods that only allow identification of a lim-
ited number of organisms within the vast microbial population
of the gut (87). The advent of highly sensitive techniques such
as quantitative PCR (qPCR) enables detection and quantification
of as little as a single copy of target DNA. This, coupled with
improved computer-based comparative metagenomic techniques,
allows for better characterization of the organisms that colonize
and comprise the intestinal microbiome (88).
A 2003 study by DeChamps et al. evaluated the colonization
ability of Lactobacillus rhamnosus Lcr 35 at doses of 108, 1010,
1012 CFU/day over a 3-week period in 12 healthy adults and found
no relation between the average number of cultured Lactobacil-
lus Lcr 35 CFU in feces and doses ingested by study subjects (86).
They demonstrated that following a 3-week post-treatment period
wherein no probiotics were administered to subjects, the CFU
levels of Lactobacillus in fecal samples were slightly decreased,
albeit similar to levels observed immediately following probiotic
treatment (86). A culture-based 2008 study by Panigrahi et al.
evaluated healthy newborns >35 weeks gestation who were given
a synbiotic (Lactobacillus plantarum and fructooligosaccharide)
for 7 days and found that the synbiotic produced rapid coloniza-
tion of the infant GI tract (within 3 days of administration) and
infants remained colonized, at decreasing rates, for several months
after therapy was stopped (89). Costa et al. evaluated 61 healthy
adults who received daily L. plantarum for differing periods of
time. L. plantarum levels were monitored over time using qPCR.
They noted a discrepancy between the daily intake of Lactobacillus
(2× 1011 cells/dose) and levels detected in feces (104 cells/g), but
noted that they were unable to account for the distribution or fate
of bacteria within the GI tract following ingestion. Interestingly,
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Table 2 | Summary of species used in recent probiotic therapy trials in preterm infants.
Reference Year Study
type
Study
size
Inclusion criteria Probiotic species studieda Daily dose Outcomes
Janvier et al. (73) 2014 Cohort 294 <32 weeks Gestational age Bifidobacterium breve 2×109 CFU Significantly decreased incidence of NEC in subjects receiving probiotics
Bifidobacterium bifidum No effect on in incidence of death
Bifidobacterium infantis No effect on rates of healthcare associated infection
Bifidobacterium longum
Lactobacillus rhamnosus
Oncel et al. (75) 2014 RCT 424 <32 weeks Gestational age Lactobacillus reuteri 1×108 CFU No effect of probiotic therapy on overall rates of NEC and/or death
Noted decreased feeding intolerance in infants receiving probiotic therapy
Jacobs et al. (76) 2013 RCT 1099 <32 weeks Gestational age Bifidobacterium infantis 1×109 CFU each Significant reduction in rates of NEC (Bell stage ≥2)
Bifidobacterium lactis No effect on rates of late-onset sepsis
Streptococcus thermophilus No effect on overall neonatal mortality
Serce et al. (77) 2013 RCT 208 <32 weeks Gestational age Saccharomyces boulardii 1×109 CFU No effect on incidence of NEC or sepsis
Birth weight <1500 g
Fernandez-
Carrocera et al.
(78)
2013 RCT 150 Preterm infants Bifidobacterium infantis 2.76×107 CFU No differences were detected in terms of NEC risk reduction
Lactobacillus rhamnosus 4.4×108 CFU Decreased frequency of NEC
Lactobacillus acidophilus 1×109 CFU Significantly decreased combined risk of NEC or death in infants receiving
probiotic therapyLactobacillus casei 1×109 CFU
Lactobacillus plantarum 1.76×108 CFU
Streptococcus thermophilus 6.6×105 CFU
Rojas et al. (79) 2012 RCT 770 Birth weight <2000 g Lactobacillus reuteri 1×108 CFU 40% Overall decrease in NEC cases, but not significant
Decreased feeding intolerance in infants receiving probiotic therapy
Al-Hosni et al.
(80)
2012 RCT 101 Birth weight <1000 g Lactobacillus rhamnosus 5×108 CFU each No effect on incidence of and mortality due to NEC
Bifidobacterium infantis Probiotic supplemented feedings improved growth velocity
Braga et al. (81) 2011 RCT 231 Birth weight <1500 g Bifidobacterium breve 3.5–3.7×107 CFU Significant decrease in incidence of NEC (Bell stage ≥2)
Samanta et al.
(82)
2009 RCT 186 <32 weeks Gestational age Bifidobacterium bifidum 2.5×109 CFU each Significant decrease in incidence of and death due to NEC
Birth weight <1500 g Bifidobacterium infantis Decreased feeding intolerance in infants receiving probiotic therapy
Bifidobacterium longum
Lactobacillus acidophilus
Lin et al. (83) 2008 RCT 234 <34 weeks Gestational age Bifidobacterium bifidum 1×109 CFU each Significant decrease in incidence of NEC or death
Birth weight <1500 g Lactobacillus acidophilus
Lin et al. (84) 2005 RCT 367 Birth weight <1500 g Bifidobacterium infantum 1×109 CFU each Significant decrease in incidence of NEC or death
Lactobacillus acidophilus
Bin Nun et al.
(85)
2005 RCT 145 Birth weight <1500 g Bifidobacterium bifidus 1×109 CFU each Significant decrease in incidence and severity of NEC
Bifidobacterium infantum
Streptococcus thermophilus
aAll species used as combination preparations of probiotics.
RCT, randomized clinical trial.
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they noted that following cessation of probiotic therapy, detec-
tion decreased to pre-intervention levels, suggesting that there is
the possibility that certain probiotics may not persist permanently
(87). Tobin et al. detected via qPCR the initial presence of 3/3
probiotic species in 83% of premature infants who ingested pro-
biotics after a week of treatment, but noted colonization by only
one species in 75% of patients four weeks after cessation of pro-
biotic therapy (90). Other studies on probiotic gut colonization
in both preterm and full-term neonates have demonstrated lower
levels of colonization (91–93) as well as transient colonization
(94). These results suggest that the effectiveness of different pro-
biotic preparations in colonizing the gut may underlie variability
in clinical trial results as noted in Table 2 (89). To date, no clin-
ical trials have correlated probiotic colonization with efficacy in
the preterm neonatal population, a population thought by many
to be more amenable to colonization (87) but with the advent
of higher resolution techniques such as qPCR to help characterize
the composition of the gut microbiome, this should be investigated
further.
Proposed mechanisms of probiotic action at the level of the gut
epithelium include enhanced epithelial barrier function, enhanced
mucosal IgA responses, direct antagonism against pathogens,
competitive exclusion of pathogens, prevention of apoptosis, pro-
duction of anti-inflammatory cytokines, and down-regulation of
pro-inflammatory pathways such as activation of nuclear factor
κB (55, 64, 68, 95). The precise mode of action of probiotics is
likely strain-dependent, and is difficult to assess due to the overall
complexity of the microbiota and its interaction with the immune
system (96). In vitro and in vivo studies have demonstrated that
Lactobacillus and Bifidobacterium exert direct effects on intestinal
epithelial barrier function by decreasing intestinal permeability
and improving intestinal epithelial resistance (96–99). In vitro
studies by Karczewski et al. with L. plantarum demonstrated a pos-
sible role for toll like receptor 2 (TLR2) as one important mediator
of epithelial cell barrier integrity (100). This study also suggested
that interplay between probiotic species and the gut epithelium
may have an immunomodulatory effect by regulating enterocyte
cytokine production (96, 100). Martin also suggests that consump-
tion of probiotic species may alter the balance of Th1/Th2 equi-
librium within the gut and may lead to prevention or treatment of
allergies or infectious diseases (96). Smelt et al. demonstrated that
short-term administration of two different lactobacillus strains (L.
plantarum WCFS1 and L. salivarius UCC118) to healthy adult mice
induces marked changes in cellular adaptive immune responses in
a strain-specific manner (101). L. plantarum was shown to increase
the frequency of regulatory T cells while decreasing responsive-
ness of Th2 cells and increasing responsiveness of CD8+ T cells
in the spleen and/or mesenteric lymph nodes, suggesting a role
for this species in modulating Th2-mediated allergic disease and
host response to viral infections that require activation of CD8+
T cells. L. salivarius also decreased responsiveness of Th2 cells but
had no effect on frequency of regulatory T cells and demonstrated
a more modest increase in CD8+ T cell responsiveness (101). The
study also demonstrated immunomodulation by Lactococcus lactis,
a non-probiotic species (101). This strain-specific immunomod-
ulation may, in part, underlie the variability in reported effects of
different probiotic species across clinical trials in humans.
Another aspect of the probiotic debate that is of paramount
importance is the question of its safety as a therapy for mitigat-
ing or preventing disease. An extensive literature review of studies
addressing the safety of probiotics by Hempel et al. in 2011 con-
cluded that “there is a lack of assessment and systematic reporting
of adverse events in probiotic intervention studies, and interven-
tions are poorly documented” (102). The authors cited several
case studies in both adults and pediatric populations describing
fungemia (n= 33) and bacteremia (n= 8) potentially associated
with probiotic administration and noted that controlled trials
did not routinely monitor for infection of test subjects receiv-
ing probiotic therapy (102). Zbinden et al. recently published a
case series of three VLBW neonates who developed Bifidobac-
terium longum bacteremia after receiving Infloran, a commonly
used commercially available probiotic preparation containing Lac-
tobacillus acidophilus and B. longum (103). Two of the three cases
resulted in a transient bacteremia, the third presented as septicemia
in the setting of NEC. In all three cases, the Bifidobacteria isolated
from patient blood cultures and in the Infloran capsule were genet-
ically and biochemically identical (103). Kitajima et al. reported
an interesting incidental finding of cross-contamination, resulting
in asymptomatic nosocomial acquisition of probiotic strains by
untreated infants in a NICU. Their group reported colonization
rates of 73 and 91% in their probiotic group at 2 and 6 weeks’ of
treatment, and colonization rates of 12 and 44% in control group
infants at the same time points (91). However, it is important to
mention that the analysis by Hempel et al. of probiotic admin-
istration did not show a statistically significant increased risk of
adverse events such as GI illness or infection (102).
There is a strong body of evidence that provides promising evi-
dence in favor of use of probiotics in the preterm population.
A 2014 Cochrane review regarding efficacy and safety of pro-
biotics for prevention and amelioration of NEC, acknowledges
the aforementioned discrepancies between trials, citing need for
improved standardized, head to head studies of type, duration,
and amount of probiotic to be used, but still strongly advocates
for their use (72). The authors of the review evaluated 24 eli-
gible trials, each with notable variability regarding enrollment
criteria, dose, formulation, and feeding regimens between stud-
ies. Despite the variability noted above, a meta-analysis of the trial
data still demonstrated a significant reduction in the incidence and
mortality of severe NEC, despite the degree of variability across
studies analyzed (72). Additionally, the included trials reported no
adverse events such as systemic infection with organisms found
in probiotic preparations used (72). As such, the authors of the
review call confidently for a change in practice based on their
results. Similar results were previously described in 2010 meta-
analysis by Deshpande et al. who evaluated 11 RCTs involving
2176 neonates. They reported that 6.56% of 1082 infants who did
not receive probiotics developed NEC compared with 2.37% of
1094 infants who did receive probiotic supplementation and that
there was a statistically significant lower relative risk {RR: 0.35
[95% confidence interval (CI): 0.23–0.55] (P < 0.00001)} of NEC
in the probiotic group. They quoted a number needed to treat
(NNT) with probiotics to prevent one case of NEC of 25 (71).
No significant heterogeneity across studies was observed in their
analysis of the data; however, it is important to remember that
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adjusting for heterogeneity in such meta-analyses may not be suf-
ficient if different probiotic strains are being used. The analysis
also confirmed lack of probiotic effect on incidence of late-onset
sepsis in preterm neonates. In light of these results, the authors
claimed that it could be considered unethical to deny probiotics
from at-risk neonates and advocated for their use without any
further placebo-controlled trials (71). A 2012 meta-analysis of 20
RCTs by Wang et al. echoed these results, finding that probiotic
administration was associated with a significantly decreased risk
of NEC and death from NEC in the VLBW preterm neonatal pop-
ulation, with no difference between treatment and placebo groups
when evaluating for risk of sepsis (70). More recently, Janvier et al.
published results of a randomized trial describing the effect of pro-
biotic administration on incidence and severity of NEC in a single
NICU since July 2011. They administered a probiotic preparation
composed of four species of Bifidobacterium to 294 infants at <32
weeks’ gestational age, and compared them to 317 infants in a
control group. They observed a statistically significant reduction
in incidence and severity of NEC, but no effect on incidence of
nosocomial infection, once again suggesting a protective role of
probiotic therapy (73).
It is important, however, that standardized large-scale trials to
more thoroughly evaluate the role of probiotics in preventing NEC
in the premature low birth weight population be done in an effort
to solve unresolved issues mentioned above (104).
Chan et al. recently called “for more stringent regulations to
hold the manufacturers of probiotics to safety standards simi-
lar to those with prescription medications so that well-designed
observational studies to rigorously evaluate the safety of vari-
ous strains and regimens can be conducted” (105). In USA, the
FDA has published the Dietary Supplement Good Manufactur-
ing Guidelines (http://www.fda.gov/Food/GuidanceRegulation/
CGMP/ucm110858.htm), effective June 2008, which require that
dietary supplements are manufactured consistently as to their
identity, purity, strength, and composition. This is to ensure that
consumers (i.e., NICUs in the present context) will have access
to dietary supplements that meet quality standards that are free
from contamination and are accurately labeled. The rule addresses
the quality of manufacturing processes for dietary supplements
and the accurate listing of supplement ingredients. However, this
rule is currently not enforceable to the stringent standards of pre-
scription medications, and is dependent on the manufacturer. The
fact remains that there are already NICUs around the world that
are/have been using probiotics to decrease rates of NEC, with pub-
lished evidence-based guidelines (74), even as the multifaceted
body of scientific literature surrounding their use grows.
DIRECTIONS FOR FURTHER RESEARCH
As research surrounding the human microbiome continues to
expand, we gather more information about its development and
function that may ultimately assist us in a better understanding
of lifelong disease processes. Because the genesis of the human
microbiome is primarily influenced by factors external to the host,
rather than intrinsic genetic factors, an understanding of these fac-
tors and how they can be manipulated could impact the balance
between health and disease beginning at or even before birth. In
time, we may be able to harness the power of this knowledge
to guide newborn delivery decision making, and to target use
of pre- and pro-biotic species to promote an as yet to be eluci-
dated “healthy” gut milieu. These potential interventions could
ultimately allow for prevention of and/or intervention against
infectious and immune-mediated disease beginning as early as
the neonatal period.
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